Nanohale AG (ETR:FYB) | WebDisclosure

BRIEF

published on 10/30/2025 at 06:35, 4 months 27 days ago

Formycon AG Schedules Conference Call for 2025 Results and Investor Engagement

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
PRESS RELEASE

published on 10/30/2025 at 06:30, 4 months 27 days ago

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
BRIEF

published on 10/21/2025 at 06:35, 5 months 5 days ago

Formycon lance le premier biosimilaire du ranibizumab en seringue préremplie en Europe

Teva Pharmaceuticals FYB201/Ranivisio® Biosimilaire Du Ranibizumab Seringue Préremplie Lancement De Formycon
BRIEF

published on 10/21/2025 at 06:35, 5 months 5 days ago

Formycon Launches Europe’s First Ranibizumab Biosimilar in Pre-filled Syringe

Teva Pharmaceuticals Ranibizumab Biosimilar Pre-filled Syringe FYB201/Ranivisio® Formycon Launch
PRESS RELEASE

published on 10/21/2025 at 06:30, 5 months 5 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 5 months 10 days ago

Actor Pharmaceuticals et Megalabs s'associent pour la commercialisation du FYB203

Formycon AG Biosimilaire Eylea® Megalabs Acteur Pharmaceutique Commercialisation Du FYB203
BRIEF

published on 10/16/2025 at 06:35, 5 months 10 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
PRESS RELEASE

published on 10/16/2025 at 06:30, 5 months 10 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF

published on 10/02/2025 at 06:35, 5 months 24 days ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
BRIEF

published on 10/02/2025 at 06:35, 5 months 24 days ago

Formycon obtient une licence américaine pour le biosimilaire d'Aflibercept

Formycon AG Lancement Sur Le Marché Américain Biosimilaire D'Aflibercept Accord Regeneron Résolution Des Litiges En Matière De Brevets

Published on 03/26/2026 at 23:00, 3 hours 24 minutes ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 4 hours 19 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 4 hours 24 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 4 hours 24 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 5 hours 24 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 5 hours 36 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 7 hours 4 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 7 hours 11 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 7 hours 15 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 7 hours 15 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 8 hours 7 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 8 hours 7 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 8 hours 24 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 8 hours 24 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 8 hours 24 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News